The effect of aggressive antihypertensive therapy in hypertensive patients with left ventricular diastolic dysfunctio

Phase 4

• Conditions: Hypertension

• Registration Number: JPRN-UMIN000002487
• Lead Sponsor: Kawasaki Medical School

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-11-01
• Study Completion: 2011-11-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with secondary hypertension 2) Patients with uncontrolled hypertension (DBP>=120mmHg) 3) Patients with uncontrolled diabetes (HbA1c>=8.0%) 4) Patients with cardiac insufficiency (over NYHA grade III) 5) Patients with renal failure (serum creatinine>=2.0mg/dl) 6) Patients with liver dysfunction (GOT or GPT>=100IU/L) 7) Patients with a previous history of gout attack or uncontrolled hyperuricemia (UA>=8.0mg/dl) 8) Patients with hyperkalemia (K>=5.5mEq/L) 9) Pregnant or breast feeding female patients, including one trying to conceive pregnancy during the planned study period 10) Patients with a history of hypersensitivity to ingredients of the study drugs 11) Patients who are considered not eligible for the study by the attending doctor due to medical reasons

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change and % change in left ventricular hypertrophy and left ventricular diastolic function after 48 weeks of treatment

Secondary Outcome Measures

Name	Time	Method
- Change and % change in left ventricular hypertrophy and left ventricular diastolic function after 24 weeks of treatment - Change and % change in blood pressure after 4, 24 and 48 weeks of treatment - Change and % change in BNP, cathecholamine 3 fractionation, hs-CRP, plasma renin activity and aldosterone levels after 24 and 48 weeks of treatment